These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26164949)

  • 41. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
    Nelson CL; Tang RS; Stillman EA
    Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic.
    Dollenmaier G; Mosier SM; Scholle F; Sharma N; McKnight KL; Lemon SM
    Virology; 2001 Mar; 281(2):216-30. PubMed ID: 11277694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E
    Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.
    Hause AM; Henke DM; Avadhanula V; Shaw CA; Tapia LI; Piedra PA
    PLoS One; 2017; 12(4):e0175792. PubMed ID: 28414749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
    Glenn GM; Fries LF; Thomas DN; Smith G; Kpamegan E; Lu H; Flyer D; Jani D; Hickman SP; Piedra PA
    J Infect Dis; 2016 Feb; 213(3):411-22. PubMed ID: 26259809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
    Front Immunol; 2019; 10():706. PubMed ID: 30984206
    [No Abstract]   [Full Text] [Related]  

  • 49. [Research Progress in Membrane Fusion of the Respiratory Syncytial Virus].
    Liu X; Wei Y
    Bing Du Xue Bao; 2015 Sep; 31(5):565-72. PubMed ID: 26738297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel antigens for RSV vaccines.
    Graham BS; Modjarrad K; McLellan JS
    Curr Opin Immunol; 2015 Aug; 35():30-8. PubMed ID: 26070108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.
    Yang CF; Wang CK; Malkin E; Schickli JH; Shambaugh C; Zuo F; Galinski MS; Dubovsky F; ; Tang RS
    Vaccine; 2013 Jun; 31(26):2822-7. PubMed ID: 23602668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP; Weisman LE
    Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA.
    McGivney JB; Bishop E; Miller K; Casas-Finet J; Yang H; Wei Z; Strouse R; Schenerman M
    J Pharm Biomed Anal; 2011 Feb; 54(3):572-6. PubMed ID: 20943340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
    Mejias A; Garcia-Maurino C; Rodriguez-Fernandez R; Peeples ME; Ramilo O
    Vaccine; 2017 Jan; 35(3):496-502. PubMed ID: 27692523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein.
    Xie Q; Wang Z; Ni F; Chen X; Ma J; Patel N; Lu H; Liu Y; Tian JH; Flyer D; Massare MJ; Ellingsworth L; Glenn G; Smith G; Wang Q
    PLoS One; 2019; 14(2):e0210749. PubMed ID: 30730999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.
    Han J; Takeda K; Wang M; Zeng W; Jia Y; Shiraishi Y; Okamoto M; Dakhama A; Gelfand EW
    Am J Respir Cell Mol Biol; 2014 Jul; 51(1):143-54. PubMed ID: 24521403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
    Caidi H; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
    PLoS One; 2012; 7(12):e51485. PubMed ID: 23300550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.
    Tang W; Li Y; Song Q; Wang Z; Li M; Zhang Q; Wang Y; Ye W; Li Y
    J Virol; 2021 Sep; 95(20):e0120521. PubMed ID: 34379500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.
    Leemans A; De Schryver M; Van der Gucht W; Heykers A; Pintelon I; Hotard AL; Moore ML; Melero JA; McLellan JS; Graham BS; Broadbent L; Power UF; Caljon G; Cos P; Maes L; Delputte P
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.